Brand-name prescription drug use among veterans affairs and medicare part d patients with diabetes

Annals of Internal Medicine

Volumn 159, Issue 2, 2013, Pages 105-114

  Gellad, Walid F ^a   Donohue, Julie M ^b   Zhao, Xinhua ^a   Mor, Maria K ^a   Thorpe, Carolyn T ^c   Smith, Jeremy ^d   Good, Chester B ^a   Fine, Michael J ^a   Morden, Nancy E ^d  

^a Veterans Affairs Center for Health Equity Research and Promotion   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d DARTMOUTH INSTITUTE FOR HEALTH POLICY AND CLINICAL PRACTICE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LONG ACTING INSULIN; ORAL ANTIDIABETIC AGENT; PRESCRIPTION DRUG;

AGED; ARTICLE; COMORBIDITY; DIABETES MELLITUS; DRUG COST; DRUG PREFERENCE; DRUG USE; FEMALE; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICARE; PATIENT REFERRAL; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; VETERAN;

AGED; DIABETES MELLITUS; DRUGS, GENERIC; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MEDICARE PART D; PRESCRIPTION DRUGS; RETROSPECTIVE STUDIES; UNITED STATES; UNITED STATES DEPARTMENT OF VETERANS AFFAIRS;

EID: 84880314186     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/0003-4819-159-2-201307160-00664     Document Type: Article

References (50)

1. Congressional Budget Office. Effects of Using Generic Drugs on Medicare's Prescription Drug Spending. September 2010. Accessed at www.cbo.gov/sites/default/files/cbofiles/ftpdocs/118xx/doc11838/09-15-prescriptiondrugs.pdf on 1 April 2012.
2. Polinski JM, Kilabuk E, Schneeweiss S, Brennan T, Shrank WH. Changes in drug use and out-of-pocket costs associated with Medicare Part D implementation: a systematic review. J Am Geriatr Soc. 2010;58:1764-79. [PMID: 20863336]
3. Donohue JM, Zhang Y, Lave JR, Gellad WF, Men A, Perera S, et al. The Medicare drug benefit (Part D) and treatment of heart failure in older adults. Am Heart J. 2010;160:159-65. [PMID: 20598987]
4. Zhang Y, Donohue JM, Lave JR, Gellad WF. The impact of Medicare Part D on medication treatment of hypertension. Health Serv Res. 2011;46:185-98. [PMID: 20880045]
5. Madden JM, Graves AJ, Zhang F, Adams AS, Briesacher BA, Ross-Degnan D, et al. Cost-related medication nonadherence and spending on basic needs following implementation of Medicare Part D. JAMA. 2008;299:1922-8. [PMID: 18430911]
6. Donohue JM, Zhang Y, Aiju M, Perera S, Lave JR, Hanlon JT, et al. Impact of Medicare Part D on antidepressant treatment, medication choice, and adherence among older adults with depression. Am J Geriatr Psychiatry. 2011;19:989-97. [PMID: 22123272]
7. Polinski JM, Donohue JM, Kilabuk E, Shrank WH. Medicare Part D's effect on the under- and overuse of medications: a systematic review. J Am Geriatr Soc. 2011;59:1922-33. [PMID: 21806563]
8. Donohue JM, Morden NE, Gellad WF, Bynum JP, Zhou W, Hanlon JT, et al. Sources of regional variation in Medicare Part D drug spending. N Engl J Med. 2012;366:530-8. [PMID: 22316446]
9. The Henry J. Kaiser Family Foundation. The Medicare Prescription Drug Benefit Fact Sheet. March 2009. Accessed at www.kff.org/medicare/upload/7044-09.pdf on 1 April 2012.
10. Huskamp HA, Epstein AM, Blumenthal D. The impact of a national prescription drug formulary on prices, market share, and spending: lessons for Medicare? Health Aff (Millwood). 2003;22:149-58. [PMID: 12757279]
11. Gellad W, Mor M, Zhao X, Donohue J, Good C. Variation in use of high-cost diabetes mellitus medications in the VA healthcare system [Letter]. Arch Intern Med. 2012;172:1608-9. [PMID: 23044980]
12. Gellad WF, Good CB, Lowe JC, Donohue JM. Variation in prescription use and spending for lipid-lowering and diabetes medications in the Veterans Affairs Healthcare System. Am J Manag Care. 2010;16:741-50. [PMID: 20964470]
13. Antos JR, Pauly MV, Wilensky GR. Bending the cost curve through marketbased incentives. N Engl J Med. 2012;367:954-8. [PMID: 22852881]
14. Berwick DM, Hackbarth AD. Eliminating waste in US health care. JAMA. 2012;307:1513-6. [PMID: 22419800]
15. Emanuel E, Tanden N, Altman S, Armstrong S, Berwick D, de Brantes F, et al. A systemic approach to containing health care spending. N Engl J Med. 2012;367:949-54. [PMID: 22852883]
16. Jacobson GA, Panangala SV, Hearne J. Pharmaceutical Costs: A Comparison of Department of Veterans Affairs (VA), Medicaid, and Medicare Policies. Washington, DC: Congressional Research Service, Library of Congress; 17 January 2007. Accessed at http://assets.opencrs.com/rpts/RL33802_20070117.pdf on 1 May 2012.
17. Frakt AB, Pizer SD, Feldman R. Should Medicare adopt the Veterans Health Administration formulary? Health Econ. 2012;21:485-95. [PMID: 21506191]
18. Gellad WF, Schneeweiss S, Brawarsky P, Lipsitz S, Haas JS. What if the federal government negotiated pharmaceutical prices for seniors? An estimate of national savings. J Gen Intern Med. 2008;23:1435-40. [PMID: 18581187]
19. Alexander GC, Sehgal NL, Moloney RM, Stafford RS. National trends in treatment of type 2 diabetes mellitus, 1994-2007. Arch Intern Med. 2008;168: 2088-94. [PMID: 18955637]
20. Miller DR, Safford MM, Pogach LM. Who has diabetes? Best estimates of diabetes prevalence in the Department of Veterans Affairs based on computerized patient data. Diabetes Care. 2004;27 Suppl 2:B10-21. [PMID: 15113777]
21. The Dartmouth Atlas of Health Care. Accessed at www.dartmouthatlas.org on 1 April 2012.
22. Drugs for type 2 diabetes. Treatment Guidelines from The Medical Letter. 2011;9:47-54.
23. Zhang Y, Baicker K, Newhouse JP. Geographic variation in the quality of prescribing. N Engl J Med. 2010;363:1985-8. [PMID: 21047217]
24. Zhang Y, Steinman MA, Kaplan CM. Geographic variation in outpatient antibiotic prescribing among older adults. Arch Intern Med. 2012;172:1465-71. [PMID: 23007171]
25. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613-9. [PMID: 1607900]
26. Young BA, Lin E, Von Korff M, Simon G, Ciechanowski P, Ludman EJ, et al. Diabetes complications severity index and risk of mortality, hospitalization, and healthcare utilization. Am J Manag Care. 2008;14:15-23. [PMID: 18197741]
27. U.S. Census Bureau. American FactFinder. Accessed at http://factfinder2.census.gov/faces/nav/jsf/pages/index.xhtml on 1 April 2013.
28. Trivedi AN, Matula S, Miake-Lye I, Glassman PA, Shekelle P, Asch S. Systematic review: comparison of the quality of medical care in Veterans Affairs and non-Veterans Affairs settings. Med Care. 2011;49:76-88. [PMID: 20966778]
29. Kerr EA, Gerzoff RB, Krein SL, Selby JV, Piette JD, Curb JD, et al. Diabetes care quality in the Veterans Affairs Health Care System and commercial managed care: the TRIAD study. Ann Intern Med. 2004;141:272-81. [PMID: 15313743]
30. Jha AK, Perlin JB, Kizer KW, Dudley RA. Effect of the transformation of the Veterans Affairs Health Care System on the quality of care. N Engl J Med. 2003;348:2218-27. [PMID: 12773650]
31. Asch SM, McGlynn EA, Hogan MM, Hayward RA, Shekelle P, Rubenstein L, et al. Comparison of quality of care for patients in the Veterans Health Administration and patients in a national sample. Ann Intern Med. 2004;141: 938-45. [PMID: 15611491]
32. Horvath K, Jeitler K, Berghold A, Ebrahim SH, Gratzer TW, Plank J, et al. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2007:CD005613. [PMID: 17443605]
33. Kesselheim AS, Misono AS, Lee JL, Stedman MR, Brookhart MA, Choudhry NK, et al. Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis. JAMA. 2008; 300:2514-26. [PMID: 19050195]
34. Matchar DB, McCrory DC, Orlando LA, Patel MR, Patel UD, Patwardhan MB, et al. Systematic review: comparative effectiveness of angiotensinconverting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension. Ann Intern Med. 2008;148:16-29. [PMID: 17984484]
35. Green JB, Ross JS, Jackevicius CA, Shah ND, Krumholz HM. When choosing statin therapy: the case for generics. JAMA Intern Med. 2013;173:229-32. [PMID: 23303273]
36. The Henry J. Kaiser Family Foundation. Analysis of Medicare Prescription Drug Plans in 2011 and Key Trends Since 2006. September 2011. Accessed at www.kff.org/medicare/upload/8237.pdf on 1 April 2012.
37. U.S. Department of Health and Human Services, Office of the Inspector General. Higher Rebates for Brand-Name Drugs Result in Lower Costs for Medicaid Compared to Medicare Part D. August 2011. Accessed at https://oig.hhs.gov/oei/reports/oei-03-10-00320.pdf on 1 May 2012.
38. Hargrave E, Hoadley J, Summer L, Merrell K. Toward Meaningful Quality and Performance Measures in Part D. Report to the Medicare Payment Advisory Commission. 28 May 2010. Accessed at www.medpac.gov/documents/Oct10_PartDQualityandPerformanceMeasuresPartD_CONTRACTOR_RS.pdf on 1 May 2012.
39. Barnett ML, Christakis NA, O'Malley J, Onnela JP, Keating NL, Landon BE. Physician patient-sharing networks and the cost and intensity of care in US hospitals. Med Care. 2012;50:152-60. [PMID: 22249922]
40. Kronick R, Gilmer TP. Medicare and Medicaid spending variations are strongly linked within hospital regions but not at overall state level. Health Aff (Millwood). 2012;31:948-55. [PMID: 22566433]
41. Choudhry NK, Shrank WH. Four-dollar generics-increased accessibility, impaired quality assurance. N Engl J Med. 2010;363:1885-7. [PMID: 21067379]
42. Zhang Y, Gellad WF, Zhou L, Lin YJ, Lave JR. Access to and use of $4 generic programs in Medicare. J Gen Intern Med. 2012;27:1251-7. [PMID: 22311333]
43. Goldman DP, Joyce GF, Zheng Y. Prescription drug cost sharing: associations with medication and medical utilization and spending and health. JAMA. 2007;298:61-9. [PMID: 17609491]
44. Shrank WH, Hoang T, Ettner SL, Glassman PA, Nair K, DeLapp D, et al. The implications of choice: prescribing generic or preferred pharmaceuticals improves medication adherence for chronic conditions. Arch Intern Med. 2006; 166:332-7. [PMID: 16476874]
45. Frank RG, Newhouse JP. Should drug prices be negotiated under part D of Medicare? And if so, how? Health Aff (Millwood). 2008;27:33-43. [PMID: 18180478]
46. Gabow P, Halvorson G, Kaplan G. Marshaling leadership for high-value health care: an Institute of Medicine discussion paper. JAMA. 2012;308:239-40. [PMID: 22669121]
47. Laine C. High-value testing begins with a few simple questions [Editorial]. Ann Intern Med. 2012;156:162-3. [PMID: 22250151]
48. Smith CD; Alliance for Academic Internal Medicine-American College of Physicians High Value. Teaching high-value, cost-conscious care to residents: the Alliance for Academic Internal Medicine-American College of Physicians Curriculum. Ann Intern Med. 2012;157:284-6. [PMID: 22777503]
49. Wilt TJ, Qaseem A. Implementing high-value, cost-conscious diabetes mellitus care through the use of low-cost medications and less-intensive glycemic control target. Arch Intern Med. 2012;172:1610-1. [PMID: 23044715]
50. Cassel CK, Guest JA. Choosing wisely: helping physicians and patients make smart decisions about their care. JAMA. 2012;307:1801-2. [PMID: 22492759]